Acute Pyelonephritis Clinical Trial
Official title:
A Randomized, Double-Blinded, Adaptive Phase 2 Study to Evaluate the Safety and Efficacy of iv or iv/po Omadacycline and iv/po Levofloxacin in the Treatment of Adults With Acute Pyelonephritis.
The purpose of this study was to evaluate the safety and efficacy of intravenous (iv) or iv/per oral (po) omadacycline as compared to iv or iv/po levofloxacin in the treatment of female adults with acute pyelonephritis.
This was a randomized (1:1:1:1:1), double-blind, double-dummy, adaptive designed, Phase 2 study. Based on review of the efficacy and microbiology data, the DMC modified the randomization algorithm, and no further participants were enrolled in the following treatment arms after May 2019: the omadacycline 200 iv/100 iv, omadacycline 200 iv/300 po or 100 iv, and omadacycline 200 iv/450 po or 100 iv arms. After this change, participants were randomized in a 1:1 ratio to either the omadacycline 200 iv/200 iv or levofloxacin arms. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05905055 -
P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales
|
Phase 3 | |
Not yet recruiting |
NCT05060419 -
Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections
|
Phase 2 | |
Recruiting |
NCT02537847 -
Sitafloxacin and Ertapenem Treatment for Acute Pyelonephritis Caused by Escherichia Coli
|
Phase 2 | |
Completed |
NCT02166476 -
Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP
|
Phase 3 | |
Completed |
NCT06141395 -
NGS-Based Assay of Blood Samples of Sepsis Patients for Rapid Bacterial Identification
|
||
Recruiting |
NCT05887908 -
Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis
|
Phase 3 | |
Completed |
NCT02420366 -
Study of Cases of Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae
|
||
Recruiting |
NCT04654507 -
Efficacy of Corticosteroids in Reducing Renal Scarring in Acute Pyelonephritis in Children
|
Phase 3 | |
Completed |
NCT04686318 -
Accuracy of Infection Biomarkers in the Investigation of Patients With Suspected Acute Pyelonephritis
|
||
Completed |
NCT04667195 -
Clinical Characteristics of Acutely Hospitalized Adults With Acute Pyelonephritis
|
||
Completed |
NCT03788967 -
Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
|
Phase 3 | |
Recruiting |
NCT05674032 -
Bacterial Metallophores in the Diagnosis of Acute Pyelonephritis
|
||
Completed |
NCT02168946 -
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
|
Phase 3 | |
Completed |
NCT01096849 -
A Study of Plazomicin Compared With Levofloxacin for the Treatment of Complicated Urinary Tract Infection (cUTI) and Acute Pyelonephritis (AP)
|
Phase 2 | |
Not yet recruiting |
NCT03630081 -
Study of Cefepime-tazobactam (FEP-TAZ) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
|
Phase 3 | |
Completed |
NCT03445195 -
Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract Infections
|
Phase 2 | |
Completed |
NCT02486627 -
A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)
|
Phase 3 | |
Completed |
NCT03477422 -
CSE-1034 (Ceftriaxone+ Sulbactam+ EDTA) Compared to Meropenem in Complicated Urinary Tract Infections (cUTIs) Caused by ESBL Producing Gram Negative Bacteria
|
Phase 3 | |
Recruiting |
NCT06059846 -
A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
|
Phase 3 | |
Completed |
NCT01928433 -
Finafloxacin for the Treatment of cUTI and/or Acute Pyelonephritis
|
Phase 2 |